Arovella Therapeutics Limited (ALA, formerly Suda Pharmaceuticals Ltd) is a biotechnology company focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumours.
Find out what a historical investment in Arovella Therapeutics Call 0.15 AUD Arovella Therapeutics 24May2027 Opt would be worth today using our ALAO stock calculator.
Buying ALAO shares in Australia can be done through an online investing platform, such as Stake. Follow the simple steps below to start investing in Arovella Therapeutics Call 0.15 AUD Arovella Therapeutics 24May2027 Opt in minutes.
Sign up with some I.D. and zero paperwork
Add funds to your account
Make your first investment in ALAO
What is the ticker symbol of Arovella Therapeutics Call 0.15 AUD Arovella Therapeutics 24May2027 Opt?
The ticker symbol for Arovella Therapeutics Call 0.15 AUD Arovella Therapeutics 24May2027 Opt is ALAO.
How much is one share of ALAO?
One share of ALAO is valued at $0.01 as of 20 November 2026.
What is the market capitalisation of Arovella Therapeutics Call 0.15 AUD Arovella Therapeutics 24May2027 Opt ALAO?
As of 20 November 2026 Arovella Therapeutics Call 0.15 AUD Arovella Therapeutics 24May2027 Opt has a market cap of $59.23M.
What is the P/E ratio of ALAO?
The Price to Earnings ratio of ALAO is -1.55.
What is the Earnings Per Share of ALAO?
The Earnings Per Share of ALAO is -$0.01.
What is the 52-week high for Arovella Therapeutics Call 0.15 AUD Arovella Therapeutics 24May2027 Opt stock?
The Arovella Therapeutics Call 0.15 AUD Arovella Therapeutics 24May2027 Opt 52-week high stock price is $0.03.
What is the 52-week low for Arovella Therapeutics Call 0.15 AUD Arovella Therapeutics 24May2027 Opt stock?
The Arovella Therapeutics Call 0.15 AUD Arovella Therapeutics 24May2027 Opt 52-week low stock price is $0.01.
Can I buy ALAO shares through Stake, an investing platform like CommSec, Selfwealth or Superhero?
Yes, the Stake investing platform allows you to buy ALAO shares and over 13,000 more stocks and ETFs across the ASX and Wall St.
This is not financial product advice nor a recommendation to invest in the securities listed. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.